Clinical Trial Update: Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating metformin glycinate for treatment of patients with COVID-19 and severe acute respiratory syndrome due to SARS-CoV-2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Due to Sars-cov-2

Drugs mentioned

• metformin glycinate (metformin glycinate)

Snippet

Sponsor: Laboratorios Silanes S.A. de C.V. | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 2 | Status: COMPLETED